Conference Coverage

Dalcetrapib Boosts HDL Without Benefiting Patients

View on the News

HDL's Clinical Relevance Remains in Doubt

What we’ve learned about HDL cholesterol is that what’s important is not the level of this material but the amount of reverse cholesterol transport that goes on in a patient, driven by apoprotein A-1.

I have studied a family with several members who have HDL cholesterol levels that are 2 or 3 mg/dL, but they have no coronary disease. That’s because they have a hyperaffinity form of apoprotein A-1, the protein that picks up cholesterol from artery walls, forms HDL, and takes the cholesterol to the liver for excretion through the cholesteryl-ester transport mechanism and reverse cholesterol transport.

If you block reverse cholesterol transport, then HDL cholesterol levels rise because they plug up, but that’s not good for patients. It’s never been clear that "cetrapib" drugs boost reverse cholesterol transport. It’s possible that what they really do is raise HDL cholesterol levels by blocking reverse cholesterol transport.

No study results have ever proven that high HDL levels correlate with improved clinical outcomes at the individual-patient level. In large groups, high HDL cholesterol levels correlate with reduced atherosclerosis, but for individual patients, especially in a setting of low levels of LDL cholesterol (either occurring naturally or induced therapeutically), high HDL levels can be worrisome. HDL cholesterol is actually a terrible biomarker of a good atherosclerotic state in individual patients.

For example, results from the AIM-HIGH study showed that treating patients with low LDL cholesterol levels (less than 70 mg/dL) with niacin raised their HDL cholesterol levels but failed to produce clinical benefit (N. Engl. J. Med. 2011;365:2255-67). That result showed it’s very possible that HDL cholesterol is not a relevant marker of reverse cholesterol transport in people whose LDL cholesterol level is below 70 mg/dL.

I like to use a garbage-truck analogy for HDL cholesterol. When the level of cholesterol in the garbage truck is low, is it because there are not enough trucks or because there is not much garbage? When patients’ LDL cholesterol is already below 70 mg/dL, do they lack enough garbage to fill their HDL garbage trucks? In patients with modest levels of LDL cholesterol, even if their HDL cholesterol level is low there may be no reason to raise it higher. On the other hand, in patients with LDL cholesterol levels above the atherogenic threshold, the higher their HDL cholesterol the better.

Dr. Thomas A. Pearson is a professor of community and preventive medicine at the University of Rochester (N.Y.). He said that he has no relevant disclosures. He made these comments in an interview.


 

AT THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION

"The results from anacetrapib and evacetrapib [in phase II studies] make a blood pressure increase [caused by either drug] unlikely," noted Dr. Schwartz. In addition, "dalcetrapib has no effect on LDL cholesterol, while anacetrapib and evacetrapib both increase LDL considerably."

But another possibility – that any agent that works primarily by raising HDL cholesterol may have little clinical benefit – cannot be dismissed based on current knowledge, Dr. Schwartz warned.

Mitchel L. Zoler/IMNG Medical Media

Dr. Alan Tall

"The modified risk produced by raising HDL cholesterol may not be significant compared with other treatments that patients get," Dr. Schwartz cautioned. In the dal-OUTCOMES trial, the average LDL cholesterol level was 76 mg/dL. Against this background, "even in the quartile of about 1,600 patients in the dalcetrapib group who achieved the highest level of HDL cholesterol, a level of about 70-75 mg/dL, we saw no apparent reduction in risk."

Concurrent with Dr. Schwartz’s report at the meeting, the results of the dal-OUTCOMES study were published online (N. Engl. J. Med. 2012 Nov. 9 [doi: 10.1056/NEJMoa1206797]).

The dal-OUTCOMES trial was sponsored by Hoffman-La Roche, the company developing dalcetrapib. Dr. Schwartz said that he has received grant support from Anthera, Resverlogix, Roche, and Sanofi. Dr. Tall had no disclosures.

Pages

Recommended Reading

Bullseye on Overuse: Fewer Interventions for Better Care
MDedge Internal Medicine
New Door Opens for Cardiac Resynchronization Therapy
MDedge Internal Medicine
Guidelines Update Approaches to Stable Ischemic Heart Disease
MDedge Internal Medicine
FDA Approves Chest-Implanted LVAD
MDedge Internal Medicine
Coumadin With an Aspirin Chaser
MDedge Internal Medicine
Long-Term Mortality Similar After Endovascular vs. Open Repair of AAA
MDedge Internal Medicine
In Type 1 Diabetes, Cardiac Measures Improved After Pancreas Transplant
MDedge Internal Medicine
DPP-4 Inhibitors for Diabetes May Cut Cardiovascular Risk
MDedge Internal Medicine
Real-World HF Findings at Odds With Clinical Trials
MDedge Internal Medicine
New Model Tops Others for Predicting Heart Disease in RA
MDedge Internal Medicine